Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly

R.C. Kaplan, PhD; D.L. Tirschwell, MD; W.T. Longstreth, Jr., MD, MPH; T.A. Manolio, MD, PhD; S.R. Heckbert, MD, PhD; D. Lefkowitz, MD; A. El-Saed, MD; and B.M. Psaty, MD, PhD

Abstract—Background: The authors studied mortality, vascular events, and preventive therapies following ischemic stroke among adults aged ≥65 years. Methods: The authors identified 546 subjects with first ischemic stroke during 1989 to 2001 among Cardiovascular Health Study participants. Deaths, recurrent strokes, and coronary heart disease (CHD) events were identified over 3.2 years (median) follow-up. Results: During the first year of follow-up, rates were 105.4/1,000 for recurrent stroke and 59.3/1,000 for CHD. After the first year, the stroke rate was 52.0/1,000 and the CHD rate was 46.5/1,000. Cardioembolic strokes had the highest mortality (185.4/1,000) and recurrence rates (86.6/1,000). Lacunar strokes had the lowest mortality (119.3/1,000) and recurrence rates (43.0/1,000). Age and male sex predicted death and CHD, but not recurrence. Outcomes did not differ by race. Following stroke, 47.8% used aspirin and 13.5% used other antiplatelet agents; 52.6% of patients with atrial fibrillation used warfarin; 31.3% of hyperlipidemic subjects, 57.0% of diabetic patients, and 81.5% of hypertensive patients were drug-treated; and 40.0% of hypertensive patients had blood pressure (BP) <140/90 mm Hg. Older subjects were less likely to use lipid-lowering therapy, women were less likely to have BP <140/90 mm Hg, and low-income subjects were less likely to use diabetes medications. Conclusions: Recurrent strokes were nearly twice as frequent as coronary heart disease (CHD) events during the first year after initial stroke, but stroke and CHD rates were similar after the first year. Preventive drug therapies were underused, which may reflect clinical uncertainty due to the lack of clinical trials among the elderly. Utilization was lower among the oldest patients, women, and low-income individuals.

Ischemic stroke is a major source of morbidity and mortality among older adults. Between the 1970s and 1990s, the number of noninstitutionalized stroke survivors in the 60- to 74-year-old US population increased from 917,000 to 1,475,000. 1 At present, more than 5% of individuals 65 to 74 years old and more than 10% of those 75 years old and older have had a prior stroke. 2 Rates of death and cardiovascular disease (CVD) events are high after ischemic stroke. However, prognosis among elderly populations of stroke survivors is not well-described. In particular, while several studies have examined mortality and recurrent stroke, 3-7 there are fewer studies of coronary events after stroke. 8-10 Preventive therapies such as antihypertensive medications, lipid-lowering therapy, aspirin, and oral anticoagulants are underutilized among stroke survivors. 11-14 Few recent datasets from the United States describe use of therapies and factors associated with underutilization among older adults with ischemic stroke.

We conducted a study of long-term prognosis and use of preventive medical therapies following first ischemic stroke among participants in the Cardiovascular Health Study (CHS) cohort of older adults. We assessed the subsequent occurrence of death and CVD events, examined the use of CVD preventive therapies, and identified risk factors for morbidity, mortality, and underutilization of medical therapies after ischemic stroke.

Methods. Study population and setting. CHS is a prospective population-based cohort study of stroke and other CVD in adults 65 years and older living in four US communities. 15 The original cohort of 5,201 participants was recruited in 1989 to 1990. In 1992 to 1993, 887 additional participants were recruited, almost all of whom lived in four primary care practices in the greater Baltimore, Maryland, area. From the Department of Epidemiology and Population Health (Dr. Kaplan), Albert Einstein College of Medicine, Bronx, NY; Departments of Neurology (Drs. Tirschwell and Longstreth), Epidemiology (Drs. Longstreth, Heckbert, and Psaty), Medicine (Dr. Psaty), and Health Services (Dr. Psaty), University of Washington, Seattle; Epidemiology and Biometry Program (Dr. Manolio), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Department of Neurology (Dr. Lefkowitz), Wake Forest University School of Medicine, Winston-Salem, NC; and Department of Epidemiology (Dr. El-Saed), University of Pittsburgh.

Supported by contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129, and N01 HC-15103 from the National Heart, Lung, and Blood Institute and grant 5R01AG009556-08 from the National Institute of Aging.

Disclosure: The authors report no conflicts of interest.

Received January 26, 2005. Accepted in final form June 6, 2005.

Address correspondence and reprint requests to Dr. Robert C. Kaplan, Department of Epidemiology and Population Health, Belfer Building, Room 1303A, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461; e-mail: rkaplan@aecom.yu.edu

Copyright © 2005 by AAN Enterprises, Inc.
whom were African American, in order to enhance the racial/ ethnic diversity of the cohort. Potential subjects were identified from Medicare eligibility lists of the Health Care Financing Ad-
mistration (HCFA). Those eligible to participate included all persons living in the household of each individual sampled, who 1) were 65 or older at the time of examination; 2) expected to remain in the area for 3 years; and 3) were able to give informed consent. Among those contacted and eligible, 57.3% were enrolled.

Study visits, questionnaires, and laboratory analyses. CHS participants completed standardized clinic examinations and ques-
tonnaires at study baseline and at 9 annual follow-up visits. Subjects who were unable to attend their local CHS clinic were offered the opportunity to complete study visits in their own home or nursing home. In addition, follow-up for mortality and CVD events was continued through phone contacts and national data-
base searches for all subjects including those who did not continue study visits. Questionnaires included an assessment of medical history, health-related behaviors, and demographic and socioeco-
nomic factors. Physical examinations included repeat right-arm blood pressures (BPs) and 12-lead resting EKGs. Current pre-
scription medication use was assessed using an inventory meth-

Definition of CVD risk factors. Prior CHD was defined as history of myocardial infarction (MI) or angina pectoris (including coronary revascularization). Hypertension was defined as prior physician diagnosis of hypertension with or without use of antihypertensive drugs. Diabetes was defined as fasting glucose ≥126 mg/dL or physician diagnosis of diabetes. Hyperlipidemia was de-
defined as LDL-cholesterol > 4.1 mmol/L (160 mg/dL) or use of lipid-lowering medications. Atrial fibrillation was defined based on study resting EKGs, which were read centrally.

Collection of CVD events. All deaths and incident CVD events during follow-up were identified through semi-annual participant contacts, notification of events by participants, and periodic searches of national administrative databases (e.g., the Medicare and Medicaid databases) and the National Death Index. Medical records for all deaths and CVD events were centrally reviewed. Neuro-
 imaging studies were available for 86% of suspected TIAs and strokes. Classification of major stroke types (i.e., ischemic or hem-
orrhagic) and etiologic subtypes of ischemic stroke was performed using criteria adopted from the SHEP study. Cardioembolic strokes were defined by autopsy evidence for embolus to the brain, or a potential source of cardiac emboli such as atrial fibrillation or flutter, MI within 6 weeks of the onset of stroke, an akinetic myocardial segment, intracerebral thrombus, valvular vegetation, prosthetic heart valve, dilated cardiomyopathy, right to left intra-
cardiac shunt, or systemic embolus. Atherosclerotic large-artery strokes were defined according to the presence of a severe athero-
sclerotic stenosis (>50% or occlusion) with evidence that the lesion was the cause of stroke. Classification of stroke subtype was based on criteria used in the Multiple Risk Factor Intervention Trial (MRFIT) and included in these analyses.

Inception cohort of ischemic stroke patients. For the analyses presented in this report, we identified an inception cohort of CHS participants who sustained a first hospitalized ischemic stroke between July 1, 2001 and July 1, 2003. There were 705 CHS subjects with nonfatal stroke and 112 with fatal stroke during follow-up, not including nonhospitalized strokes and TIAs. Of the non-fatal strokes, we excluded 56 hemorrhagic strokes and 76 strokes that were indeterminate between ischemic and hemorrhagic stroke. Of the 573 ischemic strokes, we excluded 27 who had had a history of stroke at CHS study baseline, and 26 of 55 subjects with incident ischemic stroke were included in these analyses.

Identification of prestroke and poststroke visits. For each subject with incident ischemic stroke, risk factors and medications were assessed at both the CHS visit immediately prior to stroke ("prestroke visit") and at the next CHS visit completed after stroke ("poststroke visit"). While all stroke subjects were included in analyses of subsequent mortality and CVD events, only subjects who completed poststroke visits were included in analyses of med-
ication use after stroke.

Analyses of mortality and CVD events. We examined the occurrence following ischemic stroke of 1) death, 2) recurrent stroke, and 3) CHD events. The outcome of death included all-cause mor-
tality, including fatal stroke and CHD events. Recurrent stroke included fatal and non-fatal ischemic and hemorrhagic events. CHD events included fatal and non-fatal myocardial infarction and deaths attributed to CHD. We plotted survival curves and smoothed annualized hazard curves. Multivariate Cox propor-
tional hazards regression was used to estimate adjusted hazard ratios for CHD and incident stroke risk factors associated with pre-
poststroke visit EKG indicated the presence of atrial fibrillation. Because glucose and cholesterol levels were not assessed at each study year, we used the most recent measurements available prior to stroke. Occasionally, values were missing from the visit imme-
diately preceding stroke (BP level, n = 55 missing; smoking, n = 10 missing). In these instances, we carried forward data that were collected at earlier visits.

Analyses of preventive drug therapy use following stroke. Among subjects who completed a poststroke visit, we examined use of aspirin (daily use in prior 2 weeks), other antiplatelet agents (thienopyridines and dipyridamole), and warfarin after stroke. Aspirin use was defined as either enteric-coated aspirin or a non-enteric-coated type administered either daily or on an as-needed basis. We also examined lipid-lowering medication use, diabetes medication use, antihypertensive medication use, and control of hypertension to below 140/90 mm Hg. Indications for preventive therapies were assessed at the poststroke visit. We assessed potential predictors of medication use including year of stroke, study clinic, age, sex, race, history of CHD, and household income greater or less than $21,000/year. For analyses of antiplatelet therapy and warfarin use, we also examined atrial fibrillation and stroke subtype as potential predictors. Multivariate logistic regression models that included all predictors simultaneously were used to estimate ad-
justed ORs and 95% CIs. Because of the high correlation between race/ethnicity and income, we alternated the inclusion of these two variables in multivariate models to avoid variance inflation. Subsets of stroke subjects who were missing from the poststroke visit were excluded from these analyses (income, n = 29 missing; diabetes, n = 11 missing; BP level, n = 49 missing).

Results. Subject characteristics. Of 5,639 CHS particip-
ants without a baseline history of stroke, 546 sustained an incident hospitalized non-fatal ischemic stroke (9.7% of sub-
jects). There were 66 lacunar strokes, 104 cardioem-
bolic strokes, 22 atherosclerotic large-artery strokes, and 354 indeterminate strokes (table 1). Mean age at the occurrence of stroke was 80.0 years (range 66 to 97 years), and 47% of subjects were over 80 years old. Of 71 subjects who reported race or ethnic group other than white, 69 were identified as African American. Other characteristics at the most recent visit prior to stroke appear in table 1.

Mortality and vascular events. Over 3.2 years (me-
dian) of follow-up, 57.0% of study subjects (n = 313) died, 22.0% (n = 120) sustained a recurrent stroke, and 17.4% (n = 95) sustained a subsequent CHD event (figure 1A). The estimated hazard curves indicated a progressive de-
crease in stroke risk as time elapsed since the initial stroke, from an annualized risk of approximately 10% in

836 NEUROLOGY 65 September (2 of 2) 2005
the initial year to 5% in later years (figure 1B). Of recurrent strokes, 73% (n = 87) were ischemic, 20% (n = 25) were hemorrhagic, and 7% (n = 8) were of indeterminate etiology, and the distribution of hemorrhagic, ischemic, and indeterminate strokes among recurrences did not appear to differ over time. In contrast to stroke recurrence, the hazard curves for death and CHD appeared to be relatively constant over time (see figure 1B).

During the first year after incident stroke, the incidence per 1,000 person-years was 105.4 (95% CI 79.7 to 139.5) for stroke recurrence and 59.3 (95% CI 40.9 to 85.9) for CHD events. After the first year, the incidence per 1,000 person-years was 52.0 (95% CI 41.2 to 65.6) for stroke and 46.5 (95% CI 36.6 to 59.1) for CHD. CHD rates per 1,000 person-years were 66.1 among subjects with prior CHD and 38.6 among subjects without prior CHD.

**Table 1** Characteristics of older adults with incident ischemic stroke

<table>
<thead>
<tr>
<th>Stroke subtype</th>
<th>All subjects, n = 546</th>
<th>Without poststroke visits, n = 222</th>
<th>With poststroke visits, n = 324</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lacunar</td>
<td>66 12%</td>
<td>18 8%</td>
<td>48 15%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cardioembolic</td>
<td>104 19%</td>
<td>27 12%</td>
<td>77 24%</td>
<td></td>
</tr>
<tr>
<td>Atherosclerotic large-artery stroke</td>
<td>22 4%</td>
<td>7 3%</td>
<td>15 5%</td>
<td></td>
</tr>
<tr>
<td>Other/indeterminate etiology</td>
<td>354 65%</td>
<td>170 77%</td>
<td>184 57%</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>323 59%</td>
<td>140 63%</td>
<td>183 56%</td>
<td>0.124</td>
</tr>
<tr>
<td>Men</td>
<td>223 41%</td>
<td>82 37%</td>
<td>141 44%</td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;70</td>
<td>18 3%</td>
<td>0 0%</td>
<td>18 6%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>70–75</td>
<td>93 17%</td>
<td>15 7%</td>
<td>78 24%</td>
<td></td>
</tr>
<tr>
<td>75–80</td>
<td>180 33%</td>
<td>71 32%</td>
<td>109 34%</td>
<td></td>
</tr>
<tr>
<td>&gt;80</td>
<td>255 47%</td>
<td>136 61%</td>
<td>119 37%</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>475 87%</td>
<td>191 86%</td>
<td>284 88%</td>
<td>0.581</td>
</tr>
<tr>
<td>Prior CHD (MI or angina)</td>
<td>229 42%</td>
<td>99 45%</td>
<td>130 40%</td>
<td>0.298</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>55 10%</td>
<td>17 8%</td>
<td>38 12%</td>
<td>0.121</td>
</tr>
<tr>
<td>Hypertension, treated or untreated</td>
<td>388 71%</td>
<td>161 73%</td>
<td>227 70%</td>
<td>0.533</td>
</tr>
<tr>
<td>Systolic BP, mm Hg, mean</td>
<td>143.5 24.3</td>
<td>145.5 24.4</td>
<td>142.2 24.2</td>
<td>0.115</td>
</tr>
<tr>
<td>Diastolic BP, mm Hg, mean</td>
<td>71.6 11.6</td>
<td>71.9 11.4</td>
<td>71.3 11.7</td>
<td>0.547</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>133 24%</td>
<td>41 18%</td>
<td>92 28%</td>
<td>0.008</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>128 24%</td>
<td>49 22%</td>
<td>79 24%</td>
<td>0.609</td>
</tr>
<tr>
<td>Total LDL cholesterol, mmol/L, mean</td>
<td>5.6 1.1</td>
<td>5.5 1.0</td>
<td>5.6 1.2</td>
<td>0.382</td>
</tr>
<tr>
<td>LDL cholesterol, mmol/L, mean</td>
<td>3.4 0.9</td>
<td>3.3 0.9</td>
<td>3.4 0.9</td>
<td>0.256</td>
</tr>
<tr>
<td>HDL cholesterol, mmol/L, mean</td>
<td>1.4 0.4</td>
<td>1.4 0.4</td>
<td>1.3 0.4</td>
<td>0.086</td>
</tr>
<tr>
<td>Body mass index</td>
<td>26.0 4.6</td>
<td>25.8 4.4</td>
<td>26.1 4.7</td>
<td>0.433</td>
</tr>
<tr>
<td>Smoking</td>
<td>47 9%</td>
<td>17 8%</td>
<td>30 9%</td>
<td>0.512</td>
</tr>
<tr>
<td>Income &lt;$12,000/y</td>
<td>162 31%</td>
<td>64 30%</td>
<td>98 32%</td>
<td>0.728</td>
</tr>
</tbody>
</table>

MI = myocardial infarction; CHD = coronary heart disease; BP = blood pressure; LDL = low density lipoprotein; HDL = high density lipoprotein.

Stroke subtype and events. The mortality rate per 1,000 person-years was highest for subjects who had a cardioembolic stroke (185.4, 95% CI = 147.7 to 232.9), intermediate for atherosclerotic stroke (154.9, 95% CI = 91.8 to 261.6) and indeterminate stroke (150.7, 95% CI = 130.6 to 173.8), and lowest for lacunar stroke (119.3, 95% CI = 86.5 to 164.7). Compared with lacunar stroke, cardioembolic stroke was associated with a hazard ratio of 1.81 (95% CI = 1.22 to 2.70) for death after adjustment for study year, clinic, age, and sex.

For recurrent stroke, the incidence per 1,000 person-years was highest for cardioembolic stroke (86.6, 95% CI = 60.6 to 124.9), intermediate for atherosclerotic stroke (76.4, 95% CI = 34.3 to 170.1) and indeterminate stroke (63.9, 95% CI = 50.8 to 80.6), and lowest for lacunar stroke (43.0, 95% CI = 24.4 to 75.8). Cardioembolic stroke was associated with significantly increased risk of stroke recurrence (adjusted hazard ratio = 2.01, 95% CI = 1.03 to 3.95) compared with lacunar stroke.

The incidence of CHD per 1,000 person-years was 57.9 (95% CI = 37.7 to 88.7) for cardioembolic stroke, 55.6 (95% CI = 23.1 to 137.6) for atherosclerotic stroke, 48.5 (95% CI = 28.7 to 81.8) for lacunar stroke, and 47.0 (95% CI = 36.1 to 61.2) for indeterminate stroke. There was no significant association between stroke etiology and incidence of subsequent CHD events.
Multivariate analysis of risk factors for events. In multivariate analyses, advanced age was an independent predictor of death and CHD events but not recurrent stroke (table 2). Compared with men, women had a significantly lower risk of death and also tended to have lower risk of CHD events. Other established CVD risk factors, including history of CHD, hypertension, elevated total cholesterol, diabetes, and smoking, had significant or borderline-significant associations with death and vascular events in multivariate models. There were no significant differences between white and non-white subjects in risk of death, recurrent stroke, or CHD.

Availability of poststroke visits. For the analysis of medication use after stroke, 104 subjects were ineligible because their ischemic stroke occurred after the last planned CHS visit in 1999. Of the remaining 442 subjects, 324 (73%) completed a poststroke visit. The median time from stroke to the poststroke visit was 292 days. Of poststroke visits, 69% were conducted at CHS clinics, 19% were conducted in the participant’s home, and 12% were conducted at a nursing home. Compared with 222 subjects without poststroke visits, the 324 subjects with poststroke visits were less likely to have had indeterminate stroke, were younger, and had higher prevalence of diabetes, but the two groups were otherwise similar (see table 1). Cumulative mortality was similar in subjects with and without poststroke visits (58% vs 56%), although median time to death was longer among subjects with visits (4.2 years) compared with those without visits (0.8 years). Among patients without poststroke visits, 40% of the deaths occurred within 6 months and 56% of the deaths occurred within 1 year of the initial stroke. Cumulative incidence of recurrent stroke (24% vs 19%) and CHD events (21% vs 13%) was higher in subjects with poststroke visits.

Use of preventive drug therapies following stroke. After their stroke, fewer than half of the subjects (47.8%) were using daily aspirin. Other antiplatelet agents including thienopyridines and dipyridamole were used by 13.5%. While 81.5% of 243 hypertensive subjects were receiving drug treatment, 40.0% of treated patients had BP level below 140/90 mm Hg. Use of lipid-lowering therapy among 83 hyperlipidemic patients was 31.3%. Among 98 diabetic

<table>
<thead>
<tr>
<th>Table 2 Multivariate analyses of risk factors for deaths, recurrent strokes, and CHD events among older adults with ischemic stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deaths, n = 313</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>HR*</td>
</tr>
<tr>
<td>Age, per 10 y</td>
</tr>
<tr>
<td>Female vs male</td>
</tr>
<tr>
<td>Nonwhite vs white</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
</tr>
<tr>
<td>History of CHD</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Total cholesterol per mmol/L</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>Smoking</td>
</tr>
</tbody>
</table>

* Adjusted simultaneously for all variables in table, plus stroke subtype, study clinic, and year.

HR = hazard ratio; CHD = coronary heart disease.

Figure 1. Survival and hazard curves for mortality and vascular events following ischemic stroke. (A) Survival curves for all-cause mortality, recurrent stroke, and coronary heart disease (CHD) events. (B) Smoothed annualized hazard curves for all-cause mortality, recurrent stroke, and CHD events. Time scale is years since initial ischemic stroke. Both survival and hazard curves were censored at 7.75 years, the approximate 90% percentile for duration of follow-up.
subjects, 57.0% were using insulin or oral hypoglycemic agents (see figure E-1 on the Neurology Web site at www.neurology.org).

Time trends in drug utilization following stroke. Over the period 1989 to 1999, we observed a statistically significant time trend of increasing use of lipid-lowering therapy and warfarin (figure 2). The frequency of lipid-lowering medication use among subjects with hyperlipidemia was 14.7% in 1989 to 1992, 42.9% in 1993 to 1995, and 42.9% in 1996 to 1999. Warfarin was used by 19.2% in 1989 to 1992, 14.7% in 1993 to 1995, and 26.1% in 1996 to 1999. These trends were significant after adjustment for changes over time in the distribution of strokes by study clinic, age, sex, income, and race.

Clinical factors predicting drug utilization. Multivariate regression models were used to identify independent predictors of preventive therapy use (see tables E-1, E-2, and E-3).

Antiplatelet drugs and warfarin. Aspirin was used by 39.0% of subjects with cardioembolic stroke, 46.7% with large-artery stroke, 50.0% with lacunar stroke, and 51.1% with indeterminate stroke. Only 42.1% of subjects older than 75 used aspirin, compared with 61.5% of subjects 65 to 75 years old. However, because older subjects were more likely to use non-aspirin antiplatelet agents, there was no overall difference in frequency of antiplatelet medication use by age. Aspirin or other antiplatelet medication use was 40.0% among nonwhite subjects, compared with 57.8% among white subjects (adjusted OR for nonwhite = 0.54, 95% CI = 0.26 to 1.12). Warfarin was used by 52.6% of patients with atrial fibrillation, 50.7% of subjects with cardioembolic stroke, 20.0% with large-artery stroke, 12.5% with lacunar stroke, and 8.2% with indeterminate stroke (see table E-1).

Antihypertensive medications. We did not identify any significant predictors of receiving antihypertensive treatment. However, control of BP levels to below 140/90 mm Hg was achieved in 57.7% of hypertensive men but only 36.8% of hypertensive women. Compared with men, women had an adjusted OR of 0.50 (95% CI = 0.26 to 0.95) for BP <140/90 mm Hg (see table E-2).

Lipid-lowering medications. Older individuals with hyperlipidemia were significantly less likely to use lipid-lowering medications. Use was particularly infrequent among those subjects older than 80, only 8.7% of whom were using lipid-lowering medications, compared with 40.0% of younger subjects (compared with <80 years, adjusted OR for ≥80 years = 0.13, 95% CI = 0.02 to 0.97) (see table E-3).

Diabetes medications. Only 43.3% of diabetic subjects with income below $12,000/year were receiving diabetes medications, compared with 62.3% of those with income $12,000/year or above. In multivariate analyses, the OR for receiving diabetes treatment was 0.29 (95% CI = 0.09 to 0.94) among low-income subjects compared to participants with incomes of $12,000/year or more (see table E-3).

Discussion. We report several findings regarding prognosis and utilization of preventive therapies among older individuals with first ischemic stroke. Over 3.2 years (median) of follow-up, 57.0% died and 22.0% had a recurrent stroke. Hemorrhagic strokes accounted for 20% of recurrent stroke events after ischemic stroke. Compared with previous studies, our results suggest a similar recurrence rate following ischemic stroke, but a relatively higher proportion of hemorrhagic strokes among recurrent strokes. Subsequent CHD events occurred in 17.4%, which suggests that CHD was nearly as frequent as recurrent stroke during long-term follow-up. Advanced age and male sex predicted death and CHD events, although not recurrent stroke. There were no differences in outcomes between white and non-white subjects, possibly due to small numbers of non-white subjects. Approximately 9 months after stroke, antithrombotic agents, lipid-lowering therapy, and diabetes medications were not widely used. There was evidence for less aggressive use of CVD preventive therapies among older subjects, women, and low-income individuals.

Our findings suggest a changing pattern of secondary CVD events over time that has not been identified in prior studies of stroke in the elderly. Recurrent strokes were approximately twice as frequent as CHD events during the first year after stroke (incidence rate/1,000 person-years = 105.4 for recurrent stroke and = 59.3 for CHD). Because of declining incidence of stroke over time, the rates of recurrent stroke and CHD events were similar after the first follow-up year (incidence rate/1,000 person-years = 52.0 for recurrent stroke and = 46.5 for CHD). Moreover, our data suggest a higher rate of coronary events after ischemic stroke than previously reported. For example, in a study of 1,518 Medicare enrollees with stroke, the cumulative incidence at 1 year was 6.2% for recurrent stroke and 1.6% for acute MI. Between 1 and 3 years, an additional 5.9% were found to have recurrent stroke and an additional 3.5% had acute MI. In our study, the CHD event rate in our study was substantial even among subjects free of prior MI and angina, approaching 4% per year (38.6/1,000 person-years) in this subgroup. The higher CHD rate observed in this study may be explained by more complete event identification due to active follow-up of study subjects and review of medical records for all potential CVD events and deaths.

Consistent with previous studies of ischemic
stroke survivors, we found that rates of mortality and recurrent stroke were lowest among those with lacunar stroke, while those with cardioembolic stroke had relatively high mortality and stroke recurrence rates.\(^4\)\(^5\)\(^7\) We did not find major differences in subsequent CHD event rates among patients with lacunar, cardioembolic, atherosclerotic/large-artery strokes, or indeterminate strokes. This suggests a paradox in light of prior findings that asymptomatic cardiac ischemia is more than twice as common among patients with large-artery occlusive stroke compared with those with penetrating artery disease or cryptogenic stroke.\(^23\) However, our data should be interpreted cautiously because of the large proportion of indeterminate-etiologic strokes, the relatively small sample sizes for stroke subtypes (particularly atherosclerotic stroke, \(n = 22\)), and the modest number of CHD events (\(n = 95\)).

Evidence regarding secondary stroke prevention was evolving during the study period (1989 to 2001), and our data suggested increased use of preventive drug therapies including lipid-lowering drugs and warfarin during this period. Nonetheless, we found that there is substantial room for improvement in the use of medications that may improve prognosis after stroke in the elderly.\(^24\) Approximately 9 months after stroke, only about half of subjects were using aspirin or other antiplatelet therapies, and 52.6% of atrial fibrillation patients were treated with warfarin. This may reflect concerns that the benefits of antithrombotic therapy do not outweigh the risks of major bleeding of older patients.\(^25\) We lacked information on contraindications to antiplatelet and anticoagulant therapy such as peptic ulcer disease, which may be the reason for withholding therapy in some subjects. However, these data are consistent with other reports that these therapies are underutilized, particularly in the elderly.\(^26\)\(^27\) For example, fewer than 40% of patients >65 years were using aspirin after discharge for stroke in an Ontario cohort from 1993 to 1995.\(^26\)\(^27\) In a study of VA patients with atrial fibrillation from 1998 to 2001, warfarin use among patients >75 years was below 50%, even among patients who had the highest stroke risk and were free of contraindications.\(^26\)\(^27\) The Kansas City Stroke Study assessed patients 6 months after stroke (1995 to 1998) and found that antiplatelet agents were used by 55%, and among those with atrial fibrillation, warfarin was used by 64%.\(^28\)

Nearly 20% of hypertensive subjects in this study were not receiving antihypertensive drug therapy after their stroke, consistent with use of antihypertensive treatment in other stroke survivor populations.\(^12\)\(^28\) Only 40% of drug-treated hypertensive subjects had BP levels controlled to below 140/90 mm Hg, and women had significantly poorer BP control compared with men. The inadequate treatment of hypertension may reflect controversy regarding the safety of antihypertensive therapy among elderly stroke survivors. The PROGRESS and PATS trials suggested that antihypertensives may reduce subse-
quent events in patients with prior stroke or TIA.\(^29\)\(^30\) However, these studies examined relatively young populations (PROGRESS, mean age 64 years and PATS, mean age 60 years), and up to several years had elapsed between their qualifying cerebrovascular event and study enrollment. Despite the lack of specific clinical trial evidence of risk reduction by antihypertensive treatment in older adults with recent stroke, the totality of available evidence favors active treatment and control of BP levels in this group.

Use of lipid-lowering therapy increased over time but was still only approximately 40% among hypercholesterolemic subjects in the later phase of our study period (1996 to 1999). We found that age was a strong determinant of lipid-lowering therapy use, with medications used by only 8.7% of hyperlipidemic subjects older than 80. Recent data suggest that interdisciplinary stroke care teams may achieve higher rates of statin use compared to what was observed in this population-based sample.\(^31\) We lacked complete information on achieved lipid levels, but previous studies have suggested that fewer than half of stroke survivors meet National Cholesterol Education Program (NCEP) goals for target LDL-cholesterol levels.\(^13\)\(^32\) Clinical trials support the use of lipid-lowering therapy in stroke patients up to 80 years old. The PROSPER study, which was a placebo-controlled pravastatin trial conducted specifically in the 70- to 80-year-old population, showed a reduction in vascular events among subjects with prior vascular disease (hazard ratio = 0.78, 95% CI = 0.66 to 0.93), although there was no clear benefit among those without prior vascular disease (hazard ratio = 0.94, 95% CI = 0.11 to 1.15).\(^33\) In subgroup analyses from the Heart Protection Study, which included patients 40 to 80 years old, simvastatin reduced the occurrence of coronary events (but not recurrent stroke) among patients with prior cerebrovascular events.\(^34\) It is necessary to extrapolate from existing data for the 80-years-and-older population because of the lack of clinical trials in this age group.

While tight glycemic control in diabetic patients is likely to reduce CVD events as well as microvascular complications,\(^35\) only 57% of diabetic subjects were using insulin or oral hypoglycemic agents after ischemic stroke. Aggressive management of diabetes is costly, logistically difficult to accomplish, and may be associated with risk of hypoglycemia. Our finding that low-income subjects were significantly less likely to be receiving antidiabetes medications may raise concerns about socioeconomic disparities in diabetes care. We did not directly assess hemoglobin A1c or other measures of glycemic control, and it should be noted that use of medications is only one measure of the intensity of diabetes treatment. However, our findings are consistent with prior studies documenting poor glycemic control in diabetic stroke survivors.\(^13\)

Limitations of this study include the inability to
obtain follow-up visits on all subjects after incident stroke. This may have led us to overestimate the use of preventive medications, because untreated patients may have been more likely to die without completing follow-up visits. Patients without visits were older, possibly due to survival bias, or reflecting the fact that subjects with strokes in the later years of the CHS study had less opportunity to complete poststroke visits before the end of study follow-up. However, information on mortality and CVD events was collected via telephone and by passive means (i.e., database searches), and subjects were also offered the opportunity to conduct study visits in their residence or nursing home, which may have reduced selection biases. Although the study featured standardized collection and expert review of medical record information, we lacked the depth of clinical information on stroke events that has been available in some prior studies. We based our definitions of hypertension, hyperlipidemia, diabetes, and other clinical factors on data collected at standardized study examinations. Community physicians involved in the care of study subjects may have used different criteria for defining CVD risk factors, for example relying upon repeat measurements of BP and lipids rather than measurements on a single occasion to define hypertension or hyperlipidemia. In addition, we lacked complete information on contraindications, drug intolerance, or other medical factors that may have entered into decisions regarding medication use. Assessment of medications may have been incomplete, and medications that were prescribed, but not used by study subjects, were not captured in our database.

Appendix: Participating CHS Investigators and Institutions

Steering Committee Chairman: Curt D. Furberg, MD, PhD, Wake Forest University School of Medicine. NHLBI Project Office: Jean Olson, MD, MPH. Wake Forest University School of Medicine: Gregory L. Burke, MD, Sharon Jackson, Curt D. Furberg, David S. Lefkowitz, Mary F. LYLES, Cathy Nunn, John Chen, Beverly Tucker, Harriet Weiler. Wake Forest University—ECG Reading Center: Ronald Prineas, MD, PhD. University of California, Davis: John Robbins, MD, MHS. The Johns Hopkins University: Linda P. Fried, MD, MPH. The Johns Hopkins University—MRI Reading Center: David Yousem, MD, MBA. University of Pittsburgh: Lewis H. Kuller, MD, DrPH. University of California, Irvine—Echocardiography Reading Center (follow-up): Paul Enright, MD, Tracy, PhD. University of Arizona, Tucson—Pulmonary Reading Center: John S. Gottdiener, MD. Georgetown Medical Center—Echocardiography Reading Center (baseline): Julius M. Gardin, MD. University of Vermont—Central Blood Analysis Laboratory: Daniel H. O’Leary, MD. University of Arizona, Tucson—Pulmonary Reading Center: Paul Enright, MD. Retinal Reading Center—University of Wisconsin: Ronald Klein, MD. University of Washington—Coordinating Center: Richard A. Kronmal, PhD.

References


September (2 of 2) 2005 NEUROLOGY 65 841
30. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033–1041.


Diffuse craniospinal choroid plexus papilloma with involvement of both cerebellopontine angles

F. Doglietto, MD; L. Lauretti, MD; T. Tartaglione, MD; M. Gessi, MD; E. Fernandez, MD; and G. Maira, MD, Rome, Italy

In a 16-year-old boy with headache; deficit of third, sixth, and eight left cranial nerves; and retinal hemorrhagic papilledema, MRI showed multiple craniospinal lesions (figure 1, A through D). Cysticercosis was suspected, but MRI spectroscopy suggested a neoplasm (figure 1E). The surgically removed cisterna magna solid and cystic lesions were a choroid plexus papilloma1,2 (figure 2, A and B).

The boy remains well after 1 year; only left hypoacusia persists. Serial MRIs and audiometry have shown no evidence of disease progression.

Disclosure: The authors report no conflicts of interest.

Address correspondence and reprint requests to Dr. Francesco Doglietto, Institute of Neurosurgery, Catholic University School of Medicine, L.go A. Gemelli, 8, 00168 Rome, Italy; e-mail: frandog@tiscali.it

Figure. Cranial sagittal (A) and axial (B), lumbosacral sagittal (D) T1-weighted postcontrast and cervicodorsal T2-weighted (C) images showing solid lesions in the cisterna magna, both cerebellopontine angles and the lumbosacral space, as well as multiple craniospinal cystic appearing nonenhancing lesions (A, B, arrows in C). MR spectroscopy (E): in the solid cisterna magna lesion the relative metabolic peak ratio of Cho/NAA is inverted (1.39, normal values < 1). No lactate peak was evident.

Figure 2. Histopathologic features of the cisterna magna parenchymal (A) and cystic (B) lesions, both of a benign, typical choroid plexus papilloma, composed of papillae lined by columnar epithelium (insert) (A: 250×; B: 200×; insert: 350×; hematoxylin–eosin staining). Ki67 index was less than 1%.


Diffuse craniospinal choroid plexus papilloma with involvement of both cerebellopontine angles
Neurology 2005;65;842
DOI 10.1212/01.wnl.0000167136.64675.9e

This information is current as of September 26, 2005

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/65/6/842.full

References
This article cites 1 articles, 0 of which you can access for free at:
http://n.neurology.org/content/65/6/842.full#ref-list-1

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise